Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTR1B | P28222 | 2/20 | 0.38 |
| ▸ | OGG1 | O15527 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL723663 | 1.00 | BTN3A1 (0.39) | BTN3A1ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL15837460 | 0.89 | HTT (0.41) | BTN3A1ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL10208172 | 0.89 | HTT (0.41) | BTN3A1ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL723907 | 0.89 | HTT (0.41) | BTN3A1ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL1743835 | 0.89 | HTT (0.41) | BTN3A1ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL10208163 | 0.89 | ALDH1A1 (0.40) | BTN3A1ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL14941788 | 0.88 | ALDH1A1 (0.39) | BTN3A1ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL14941789 | 0.88 | ALDH1A1 (0.39) | BTN3A1ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL1274611 | 0.87 | CNR2 (0.41) | BTN3A1ALDH1A1KDM4EHPGDKMT2A | |
| SCHEMBL1273006 | 0.86 | BTN3A1 (0.45) | BTN3A1ALDH1A1HSD17B10HPGDOGG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140286903-A1 | Substituted Purine Nucleosides, Phosphoramidate and Phosphordiamidate Derivatives for Treatment if Viral Infections | INHIBITEX, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140286903-A1 | Substituted Purine Nucleosides, Phosphoramidate and Phosphordiamidate Derivatives for Treatment if Viral Infections | INHIBITEX, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| US-20140286903-A1 | Substituted Purine Nucleosides, Phosphoramidate and Phosphordiamidate Derivatives for Treatment if Viral Infections | INHIBITEX, INC. (US) | 2014-09-25 | — | — | US | disclosed |
| EP-2776438-A1 | SUBSTITUTED PURINE NUCLEOSIDES, PHOSPHORAMIDATE AND PHOSPHORDIAMIDATE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS | Inhibitex, Inc. (US) | 2014-09-17 | — | — | EP | disclosed |
| US-8759318-B2 | Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections | INHIBITEX, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759318-B2 | Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections | INHIBITEX, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8759318-B2 | Phosphoramidate derivatives of guanosine nucleoside compounds for treatment of viral infections | INHIBITEX, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| WO-2013070887-A1 | SUBSTITUTED PURINE NUCLEOSIDES, PHOSPHORAMIDATE AND PHOSPHORDIAMIDATE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS | INHIBITEX, INC. (US) | 2013-05-16 | — | — | WO | disclosed |
| WO-2013070887-A1 | SUBSTITUTED PURINE NUCLEOSIDES, PHOSPHORAMIDATE AND PHOSPHORDIAMIDATE DERIVATIVES FOR TREATMENT OF VIRAL INFECTIONS | INHIBITEX, INC. (US) | 2013-05-16 | — | — | WO | disclosed |
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2012-03-01 | — | — | US | disclosed |
| WO-2010081082-A2 | PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | UNIVERSITY COLLEGE OF CARDIFF CONSULTANTS LIMITED (GB) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120052046-A1 | Phosphoramidate Derivatives of Guanosine Nucleoside Compunds for Treatment of Viral Infections | PNP, SAMHD1, MTAP | BTN3A1 4601/4885ALDH1A1 4139/4885KDM4E 4140/4885 |
| US-20140286903-A1 | Substituted Purine Nucleosides, Phosphoramidate and Phosphordiamidate Derivatives for Treatment if Viral Infections | PNP, TYMP, SLC29A1 | BTN3A1 2881/4885ALDH1A1 2038/4885KDM4E 3847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.